Eva Wesley, Author at Born2Invest

Eva Wesley

Eva Wesley is an experienced journalist, market trader, and financial executive. Driven by excellence and a passion to connect with people, she takes pride in writing think pieces that help people decide what to do with their investments. A blockchain enthusiast, she also engages in cryptocurrency trading. Her latest travels have also opened her eyes to other exciting markets, such as aerospace, cannabis, healthcare, and telcos.

Born2Invest uses cookies in order to improve your experience and make further customizations to how we present our content. By continuing to use our website, you accept and give your consent to our practices as described in the following: our revised Privacy Policy, Cookie Policy, and Terms of Use.

Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Born2Invest

Eva Wesley

Stories By Eva Wesley

The AECC Provides 29.4 Million in Aid for 233 Cancer Research Projects

Biogen Reaches $9.8 Billion in Revenue in 2023, Down 3%

Qube Research & Technologies Increases its Short Position in Grifols to 1.23%

Eight Out of Ten Spanish Companies in the Biotech Sector Increase R&D Investment

UrbanFisio Closes an Investment Round of One Million Euros

Almirall to Collaborate with the Center for Genomic Regulation to Develop New Treatments

Novo Nordisk Buys Catalent for 10.66 Billion to Produce More Wegovy

Eli Lilly Earns 16% Less Due to Spending on R&D and Acquisitions

BlackRock Increases its Stake in Grifols in the Midst of a Judicial Struggle with Gotham

Almirall and Microsoft Join Forces to Develop Treatments for Skin Diseases